Name: Biofargo hMODM Human MSC Osteogenic Differentiation Medium
Brand: Biofargo
SKU: BFHMODM100

How long does osteogenic differentiation take using Biofargo hMODM?

Human MSC osteogenic differentiation is typically performed for approximately 14–21 days depending on cell status and mineralization development.

Description

Successful osteogenic differentiation of human mesenchymal stem cells (hMSCs) requires a controlled induction environment that supports cellular transition from multipotent stromal cells toward osteoblast-like phenotypes. In routine MSC differentiation workflows, inconsistent induction conditions, variable cell states, and differences in mineralization efficiency may influence downstream analysis of osteogenic potential.

Biofargo hMODM Human MSC Osteogenic Differentiation Medium is a complete osteogenic differentiation medium specifically developed for human mesenchymal stem cell osteogenesis induction research. The optimized formulation contains essential and non-essential amino acids, vitamins, hormones, growth factors, trace minerals, and low concentrations of fetal bovine serum to support human MSC differentiation toward the osteogenic lineage.

This human MSC osteogenic differentiation medium provides a convenient solution for researchers studying osteoblast differentiation, bone formation biology, and mesenchymal stem cell differentiation pathways. Biofargo hMODM supports workflows requiring evaluation of calcium deposition, mineralized extracellular matrix formation, and osteogenic differentiation characteristics.

Specifications

Product Name	Biofargo hMODM Human MSC Osteogenic Differentiation Medium
Product Type	Human mesenchymal stem cell osteogenic differentiation medium
SKU	BFHMODM100
Volume	100 mL
Application	Human MSC osteogenic induction and osteoblast differentiation research
pH	7.1–7.3
Osmolality	280–320 mOsm/kg·H₂O
Endotoxin	≤0.25 EU/mL
Bacteria/Fungi	Negative
Mycoplasma	Negative
Appearance	Pink clear liquid
Storage	-20°C
Shelf Life	12 months
Research Grade	For research use only

Features

Optimized human MSC osteogenic differentiation medium for osteoblast lineage induction research
Complete formulation containing amino acids, vitamins, hormones, growth factors and trace minerals
Supports mesenchymal stem cell transition toward osteogenic phenotypes
Suitable for evaluation of calcium mineralization and extracellular matrix formation
Designed for human MSC osteogenesis induction workflows
Compatible with osteogenic differentiation analysis including Alizarin Red staining
Controlled quality specifications including endotoxin, sterility and mycoplasma testing

Performance Data

Human MSC Osteogenic Differentiation Morphology Analysis

Biofargo hMODM was evaluated during human mesenchymal stem cell osteogenic differentiation to observe cellular morphology changes during induction culture. During osteogenic induction, human MSCs gradually exhibit morphological changes associated with osteogenic lineage commitment.

Human mesenchymal stem cell osteogenic differentiation morphology during induction culture with Biofargo hMODM medium

Representative microscopy images showing human MSC morphology during osteogenic differentiation culture with Biofargo hMODM. Cell morphology changes may be observed throughout the induction period as cells progress toward osteogenic differentiation.

Calcium Mineralization Detection by Alizarin Red Staining

Osteogenic differentiation commonly involves extracellular matrix mineralization and calcium deposition. Biofargo hMODM supports human MSC osteogenic differentiation workflows requiring mineralization evaluation through calcium staining methods.

Alizarin Red staining of calcium mineralization in human MSC osteogenic differentiation culture

Representative Alizarin Red staining results following osteogenic induction demonstrate calcium-rich mineralized nodule formation after differentiation culture. This analysis can be used for evaluating osteogenic differentiation potential and mineralization capability.

Recommended Osteogenic Differentiation Workflow

Human MSC Induction Procedure

Biofargo hMODM is designed for researchers performing human MSC osteogenic differentiation experiments. A typical workflow includes cell preparation, induction medium replacement, differentiation culture and endpoint analysis.

Culture human MSCs under appropriate expansion conditions until cells reach approximately 70–80% confluence.
Replace growth medium with Biofargo hMODM osteogenic differentiation medium to initiate osteogenic induction.
Maintain differentiation culture at 37°C with 5% CO₂ for approximately 14–21 days.
Replace induction medium every 2–3 days and monitor cell morphology changes.
Evaluate osteogenic differentiation using calcium deposition staining or related osteogenic assays.

The optimal differentiation duration may vary depending on cell source, passage number, culture conditions and experimental requirements.

Applications

Biofargo hMODM Human MSC Osteogenic Differentiation Medium is designed for research applications involving human mesenchymal stem cell differentiation, osteoblast development and bone-related cellular studies.

Human mesenchymal stem cell osteogenic differentiation research
Osteoblast differentiation studies using human MSCs
MSC osteogenesis induction and lineage commitment analysis
Bone formation and mineralization research
Evaluation of calcium deposition during MSC differentiation
Alizarin Red staining-based osteogenic differentiation analysis
Mesenchymal stem cell multipotency and differentiation potential studies
Bone tissue engineering research involving human MSC models
Biomaterial evaluation requiring osteogenic differentiation assessment
Stem cell biology studies investigating osteogenic signaling pathways

Why Choose Biofargo hMODM Human MSC Osteogenic Differentiation Medium?

Human mesenchymal stem cell differentiation experiments often require stable induction conditions to achieve reproducible osteogenic outcomes. Differences in cell preparation, medium formulation and induction environment may affect osteoblast differentiation efficiency and mineralization results.

Biofargo hMODM provides a ready-to-use osteogenic differentiation medium optimized for human MSC research workflows. The formulation combines essential nutrients, differentiation-supporting components and controlled quality specifications to simplify osteogenic induction experiments.

By providing a consistent culture environment, Biofargo hMODM helps researchers evaluate human MSC osteogenic potential through morphological observation, calcium mineralization analysis and osteogenic differentiation assays.

FAQ

What is Biofargo hMODM Human MSC Osteogenic Differentiation Medium used for?

Biofargo hMODM is a human mesenchymal stem cell osteogenic differentiation medium designed to induce differentiation of human MSCs toward osteoblast-like cells for bone formation and stem cell differentiation research.

What cells can be used with Biofargo hMODM?

Biofargo hMODM is designed for research involving human mesenchymal stem cells. It can be used for osteogenic differentiation studies of human MSC populations from commonly investigated sources.

How long does human MSC osteogenic differentiation take with Biofargo hMODM?

The recommended osteogenic induction period is approximately 14–21 days. The final differentiation duration should be determined according to cell status, mineralization development and experimental objectives.

How often should the osteogenic differentiation medium be replaced?

During osteogenic induction culture, Biofargo hMODM should typically be replaced every 2–3 days according to the experimental workflow and cell condition.

How can osteogenic differentiation be evaluated?

Human MSC osteogenic differentiation can be evaluated using methods such as Alizarin Red staining for calcium deposition, alkaline phosphatase analysis and detection of osteogenic marker expression.

Does Biofargo hMODM contain antibiotics?

No. Biofargo hMODM does not contain penicillin or streptomycin. Additional antibiotics may be added separately if required for specific experimental workflows.

What quality tests are performed for Biofargo hMODM?

Biofargo hMODM is tested for endotoxin level, bacterial/fungal contamination and mycoplasma contamination. The product specification includes endotoxin ≤0.25 EU/mL, negative bacteria/fungi detection and negative mycoplasma testing.

How should Biofargo hMODM be stored?

Biofargo hMODM should be stored at -20°C. The product has a shelf life of 12 months under recommended storage conditions.

Is Biofargo hMODM intended for clinical use?

No. Biofargo hMODM is intended for research use only and is designed for laboratory research applications involving human MSC osteogenic differentiation.

hMODM - Human MSC Osteogenic Differentiation Medium